Log in

NYSE:NVRO - Nevro Stock Price, Forecast & News

+0.51 (+0.45 %)
(As of 12/6/2019 03:10 AM ET)
Today's Range
Now: $113.35
50-Day Range
MA: $98.28
52-Week Range
Now: $113.35
Volume343,355 shs
Average Volume514,038 shs
Market Capitalization$3.51 billion
P/E RatioN/A
Dividend YieldN/A
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments



Sales & Book Value

Annual Sales$387.29 million
Book Value$8.14 per share


Net Income$-49,210,000.00


Market Cap$3.51 billion
Next Earnings Date2/20/2020 (Estimated)

Receive NVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVRO and its competitors with MarketBeat's FREE daily newsletter.

Nevro (NYSE:NVRO) Frequently Asked Questions

What is Nevro's stock symbol?

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

How were Nevro's earnings last quarter?

Nevro Corp (NYSE:NVRO) posted its earnings results on Wednesday, November, 6th. The medical equipment provider reported ($0.58) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.85) by $0.27. The medical equipment provider earned $100.16 million during the quarter, compared to the consensus estimate of $92.27 million. Nevro had a negative return on equity of 46.35% and a negative net margin of 25.94%. The business's quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the business earned ($0.37) EPS. View Nevro's Earnings History.

When is Nevro's next earnings date?

Nevro is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Nevro.

What price target have analysts set for NVRO?

9 Wall Street analysts have issued twelve-month price objectives for Nevro's shares. Their forecasts range from $65.00 to $115.00. On average, they anticipate Nevro's stock price to reach $88.22 in the next year. This suggests that the stock has a possible downside of 22.2%. View Analyst Price Targets for Nevro.

What is the consensus analysts' recommendation for Nevro?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nevro.

What are Wall Street analysts saying about Nevro stock?

Here are some recent quotes from research analysts about Nevro stock:
  • 1. According to Zacks Investment Research, "Nevro exited the second quarter on a weak note. The company’s domestic and international revenues deteriorated year over year. Loss per share widened on a year-over-year basis. Significant contraction in gross margin raises concern. Surge in operating expenses adds to the woes. The stock is overvalued at the moment. On the bright side, increased R&D expenses reflect focus on innovation. The guidance for 2019 is also promising. Management is further optimistic about the long-term prospects of the flagship Senza II platform, launched late last year. Nevro is also on track to launch its next product platform, Omnia, which is expected to lend the company a competitive edge in the near future. The stock has outperformed the industry over the past year." (8/13/2019)
  • 2. Northland Securities analysts commented, "We are introducing our FY20 numbers, and our rating / PT remains the same." (1/11/2019)

Has Nevro been receiving favorable news coverage?

News stories about NVRO stock have been trending somewhat positive on Friday, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Nevro earned a news impact score of 2.0 on InfoTrie's scale. They also assigned news stories about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Nevro.

Are investors shorting Nevro?

Nevro saw a increase in short interest in the month of October. As of October 15th, there was short interest totalling 3,880,000 shares, an increase of 25.6% from the September 15th total of 3,090,000 shares. Based on an average daily volume of 400,900 shares, the days-to-cover ratio is currently 9.7 days. Currently, 13.1% of the company's shares are short sold. View Nevro's Current Options Chain.

Who are some of Nevro's key competitors?

What other stocks do shareholders of Nevro own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), Micron Technology (MU), Celgene (CELG), AbbVie (ABBV), Adobe (ADBE), Gilead Sciences (GILD), Incyte (INCY), Lam Research (LRCX) and Starbucks (SBUX).

Who are Nevro's key executives?

Nevro's management team includes the folowing people:
  • Mr. Andrew H. Galligan, Chief Financial Officer (Age 63)
  • Mr. Patrick Schmitz, VP of Operations (Age 59)
  • Mr. Kashif Rashid, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 45)
  • Mr. Doug Alleavitch, VP of Quality (Age 58)
  • Mr. D. Keith Grossman, Pres, CEO & Director (Age 59)

Who are Nevro's major shareholders?

Nevro's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (2.31%), Redmile Group LLC (2.08%), Point72 Asset Management L.P. (0.72%), Pictet Asset Management Ltd. (0.65%), Massachusetts Financial Services Co. MA (0.58%) and Millennium Management LLC (0.21%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Elizabeth H Weatherman, Kevin C Oboyle, Shawn Mccormick and Wilfred E Jaeger. View Institutional Ownership Trends for Nevro.

Which institutional investors are selling Nevro stock?

NVRO stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Pictet Asset Management Ltd., Massachusetts Financial Services Co. MA, State Street Corp, SG Americas Securities LLC, Rice Hall James & Associates LLC, First Trust Advisors LP and Partner Investment Management L.P.. Company insiders that have sold Nevro company stock in the last year include Andrew H Galligan, Doug Alleavitch and Shawn Mccormick. View Insider Buying and Selling for Nevro.

Which institutional investors are buying Nevro stock?

NVRO stock was purchased by a variety of institutional investors in the last quarter, including Redmile Group LLC, Point72 Asset Management L.P., Voloridge Investment Management LLC, California Public Employees Retirement System, Man Group plc, Lisanti Capital Growth LLC, Tamarack Advisers LP and Creative Planning. Company insiders that have bought Nevro stock in the last two years include Elizabeth H Weatherman and Kevin C Oboyle. View Insider Buying and Selling for Nevro.

How do I buy shares of Nevro?

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Nevro's stock price today?

One share of NVRO stock can currently be purchased for approximately $113.35.

How big of a company is Nevro?

Nevro has a market capitalization of $3.51 billion and generates $387.29 million in revenue each year. The medical equipment provider earns $-49,210,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Nevro employs 804 workers across the globe.View Additional Information About Nevro.

What is Nevro's official website?

The official website for Nevro is http://www.nevro.com/.

How can I contact Nevro?

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]

MarketBeat Community Rating for Nevro (NYSE NVRO)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  405 (Vote Outperform)
Underperform Votes:  284 (Vote Underperform)
Total Votes:  689
MarketBeat's community ratings are surveys of what our community members think about Nevro and other stocks. Vote "Outperform" if you believe NVRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/6/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel